Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure.

Geissbühler, Yvonne; Vile, Jere; Koren, Gideon; Guennec, Morgane; Butzkueven, Helmut; Tilson, Hugh; MacDonald, Thomas M; Hellwig, Kerstin

Geissbühler, Yvonne; Vile, Jere; Koren, Gideon; Guennec, Morgane; Butzkueven, Helmut; Tilson, Hugh; MacDonald, Thomas M; Hellwig, Kerstin.

Afiliación

Geissbühler Y; Novartis Pharma AG, WSJ-027.3.021.01, Basel, 4002, Switzerland.
Vile J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Koren G; Western University, ON, Canada.
Guennec M; IQVIA, Saint Ouen, Paris, France.
Butzkueven H; MS and Neuroimmunology Unit, Central Clinical School, Monash University, The Alfred Centre, Victoria, Australia.
Tilson H; University of North Carolina School of Public Health, Chapel Hill, NC, USA.
MacDonald TM; Ninewells Hospital and Medical School, Dundee, UK.
Hellwig K; Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany.

Ther Adv Neurol Disord ; 11: 1756286418804760, 2018.

Article en En | MEDLINE | ID: mdl-30542374

Palabras clave

congenital malformations; fingolimod; miscarriages; multiple sclerosis; pregnancy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Neurol Disord Año: 2018 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google